Phase 2 N=40 APBI Proton Feasibility and Phase II Study
Stage IA-IIA Breast Cancer
Primary: Feasibility and the Acute Toxicity Profile of Accelerated Partial Breast Radiation Using Protons — 11; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
Hepatitis D, Chronic
Primary: Double-blind: Part 1: Percentage of Participants With HDV Ribonucleic Acid (RNA) >=2 log10 IU/mL Decline From Baseline or HDV RNA Target Not Detected (TND) in…
Phase 2 N=25 Use of a GLP-1R Agonist to Treat Opioid Use Disorder
Opiate Substitution Treatment · Opioid-Related Disorders
Primary: Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS) — -5.00; -13.34 score on a scale
Phase 2 N=245 A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.9; -1.8; -2.1; -1.1 Percentage-point of HbA1c — p=0.0002
Phase 2 N=52 Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
Gonorrhoea
Primary: Rectal Mucosal IgG Concentrations (Geometric Mean Titers [GMT]) Against N. Gonorrhoeae Outer Membrane Vesicle (OMV) Antigen Ng1291 — 0.07; 0.072; 0.089; 0.097 titer
Phase 2 N=65 Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Fuchs' Endothelial Corneal Dystrophy
Primary: Central Corneal Endothelial Cell Density (ECD) at Week 12 — 530.86; 468.02; 228.05 cells/mm2 — p=0.0065
Phase 2 N=53 Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
Oral Mucositis
Primary: Duration of Severe Oral Mucositis (SOM) — 22.9; 27.7; 35.2; 37.8 Days
Phase 2 N=120 MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
Bacterial Infections
Primary: Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline — 72; 35 Participants
Phase 2 N=150 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Primary: Maximum Tolerated Dose of 5-azacytidine in the Combination of Nivolumab With Dihydro-5-azacytidine — 75; 75; 75 Mg/m^2
Phase 2 N=69 Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 — -3.61; -2.42 ANs — p=0.0215
Phase 2 N=10 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Primary: Percentage of Participants With Reduction in Serum Lactate Dehydrogenase (LDH) Levels Within the First 4 Weeks of LFG316 Treatment as Measured by Response Rate — 10; 0…
Phase 2 N=43 A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes
Type 2 Diabetes
Primary: Change in Glycosylated Hemoglobin — -1.2; -0.30; -1.4; -0.5 percentage of glycosylated hemoglobin — p=.017
Phase 2 N=21 Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women
Vulvovaginal Atrophy · Vasomotor Symptoms
Primary: Number of Participants With Treatment Emergent Adverse Events — 11; 10 Participants
Phase 2 N=34 Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
Pneumonia, Viral
Primary: Number of Participants Free From Respiratory Failure at Day 7 — 12; 6 Participants
Phase 2 N=20 Fecal Microbiota Transplant (FMT) in Melanoma Patients
Melanoma
Primary: Objective Response Rate (ORR) — 2; 1 Participants